Artimes™ Pro Clinical Trial Completed Successfully in U.S.
Release time:
2021-04-07
A clinical trial of Artimes™ Pro, a rapid exchange coronary balloon dilatation catheter manufactured by BrosMed Medical, has been successfully completed in the United States. The diameters of the balloon dilatation catheters are 1.0 mm and 1.25 mm. The crossing profile of 1.0mm balloon is ultra-small of 0.0218’’, which is suitable for CTO lesions.
A clinical trial of Artimes™ Pro, a rapid exchange coronary balloon dilatation catheter manufactured by BrosMed Medical, has been successfully completed in the United States. The diameters of the balloon dilatation catheters are 1.0 mm and 1.25 mm. The crossing profile of 1.0mm balloon is ultra-small of 0.0218’’, which is suitable for CTO lesions.
The Artimes™ Pro clinical trial is a prospective, non-randomized, open clinical trial led by Dr. Jasvinder Singh of Washington University in the United States. All 60 patients in the trial presented with 70-100% coronary stenosis/CTO lesions. The ratio of 1.0mm and 1.25mm balloons used in the clinical trial was 3:1. The final procedural success rate reached 97.9%, and no adverse events related to the device occurred.
BroMed Medical has been deeply engaged in the field of coronary angioplasty for many years. The Artimes™ ( K141025, 1.5-4.0 mm) balloon portfolio has been sold in United States since 2015 and distributed in more than 50 countries around the world. Based on its proven manufacturing process and technology, Artimes™ Pro, a pre-dilatation PTCA balloon for stenotic CTO lesions, is estimated to get 510K clearance in 2021.
Join with Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announced CE MDR Approval of New Generation Conger™ Plus Hydrophilic Guidewires
Designed for superior crossability and maneuverability in peripheral interventions, Conger Plus now offers 116 models with expanded sizes (OD 0.018'' to 0.038'') and lengths (up to 300cm).
2025-04-25
Meet BrosMed at ESC Congress 2024
BrosMed Medical is delighted to participate in the ESC Congress 2024 from August 30th to September 2nd in London, UK.
2024-08-15
BrosMed Medical Announces Scott J. Addonizio as Chief Operating Officer
2024 August 1st – BrosMed Medical is pleased to announce the appointment of Scott J. Addonizio as its Chief Operating Officer (COO), effective immediately. Mr. Scott J. Addonizio brings a wealth of experience and expertise to BrosMed, with a distinguished career spanning almost 30 years in the medical device industry. Prior to joining BrosMed, Mr. Addonizio served as SVP at Cordis and COO at MedAlliance Swiss Medical Technology.
2024-08-01
CTO&CHIP PCI – Insights from the clinical practice (Ⅱ)
July 30, 2024 @16:00-17:30 (Beijing Time) Join BrosMed Medical on Tuesday, July 30 for an enlightening discussion that unites cardiologists from Malaysia, China, India, Tunisia and Portugal, where clinical expertise harmoniously fuses with CTO&CHIP innovation. At this exclusive webinar, we’re orchestrating a confluence of valuable insights, drawing from the collective wisdom of seasoned interventional cardiologists.
2024-07-26
BrosMed Announced CE MDR Approval of New Generation PTA SC Balloon Dilatation Catheters
May 27, 2024- BrosMed announced that it receives European Medical Device Regulation (MDR) certification for the New Generation PTA SC Balloon Dilatation Catheters (Brand Name: Polux™ Pro 014, Minerva™ Pro 018 and Atropos™ Pro 035).
2024-05-27